Nice!
$Adaptimmune Therapeutics(ADAP.US$ Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma," details clinical and translational results from afami-cel's SPEARHEAD-1 trial (NCT04044768).
Dennis Williams, PharmD., Senior Vice President, Late-Stage Development, Adaptimmune: "It is exciting to see the Lancet share the afami-cel SPEARHEAD-1 trial results in advanced sarcomas with the broader clinical and research communities. The study further demonstrates the ability of engineered T-cell therapies to effectively target solid tumors and we are eager to introduce the first engineered T-cell therapy, afami-cel, to more patients later this year."
Dr. Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, lead author of the publication: "The reported findings are clinically impactful, considering the current standard of care and limited therapies available in advanced sarcomas. Treatment with afami-cel resulted in 39% overall response rate in synovial sarcoma with durable responses. These results suggest that a one-time treatment with afami-cel has the potential to extend life while allowing responders to go off chemotherapy. The publication of this data further validates the potential of afami-cel to offer a new tool to address the unmet needs of people diagnosed with these often-devastating diseases."
Dennis Williams, PharmD., Senior Vice President, Late-Stage Development, Adaptimmune: "It is exciting to see the Lancet share the afami-cel SPEARHEAD-1 trial results in advanced sarcomas with the broader clinical and research communities. The study further demonstrates the ability of engineered T-cell therapies to effectively target solid tumors and we are eager to introduce the first engineered T-cell therapy, afami-cel, to more patients later this year."
Dr. Sandra D'Angelo, M.D., Sarcoma Medical Oncology, Memorial Sloan Kettering Cancer Center, lead author of the publication: "The reported findings are clinically impactful, considering the current standard of care and limited therapies available in advanced sarcomas. Treatment with afami-cel resulted in 39% overall response rate in synovial sarcoma with durable responses. These results suggest that a one-time treatment with afami-cel has the potential to extend life while allowing responders to go off chemotherapy. The publication of this data further validates the potential of afami-cel to offer a new tool to address the unmet needs of people diagnosed with these often-devastating diseases."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
买跌不追涨 : You are so hardworking, morning to night. Don't you need to eat and take a break?
TrytosaveabitOP 买跌不追涨: Work is good for the soul! Hehehe
买跌不追涨 TrytosaveabitOP: Pay attention to eye and body health
TrytosaveabitOP 买跌不追涨: Absolutely! And thank you kindly!
买跌不追涨 TrytosaveabitOP: making money is a good thing but healthy is also important
TrytosaveabitOP 买跌不追涨: Couldn’t agree more! Without your health the money is worthless!
TrytosaveabitOP 买跌不追涨: